Your Annual COVID Shot Just Got a New Name You Can't Pronounce

There's also a stricter evidence bar for some groups. Updated vaccines for adults 65 and older and people with underlying conditions can be approved based on immune-response data alone. But for healthy younger adults and children, the FDA may require randomized, placebo-controlled trials, which is a higher standard than the typical flu update pathway. Pfizer's Comirnaty XFG, for instance, was approved for adults 65+ and people ages 5–64 with at least one risk factor for severe COVID. Not everyone gets the same green light.

Follow the Money

Updated vaccines are a public health measure, sure. They're also a business. And the revenue gap between the three manufacturers is enormous.

Pfizer is guiding for roughly $5 billion in COVID-19 product revenue for full-year 2026. That's out of a total revenue target of $59.5 to $62.5 billion, making COVID still a meaningful (if shrinking) slice of the pie.

Novavax lives in a completely different universe. The company expects just $35 to $45 million in direct Nuvaxovid product sales for 2026, with most of that revenue landing in Q4 when vaccination season peaks. Novavax has handed lead commercial responsibility to Sanofi in several markets, so its total adjusted revenue (excluding Sanofi supply sales, royalties, and milestones) sits in the $235 to $275 million range. It's the scrappy indie band opening for two arena headliners.

Moderna sits in the middle but has been cagey with specifics. The company said 2026 revenue could grow by up to 10% year over year.

The Uptake Problem Nobody Wants to Talk About

Here's the uncomfortable truth buried under all the authorization headlines: you can approve the most perfectly matched vaccine in history, and it won't matter if nobody rolls up their sleeve.

The numbers from the 2025–2026 season are sobering. By late February 2026, only 17.5% of U.S. adults had gotten their updated COVID shot. Among Medicare beneficiaries 65 and older (the group most likely to be hospitalized), coverage was just 22.6% by late March. Children? A dismal 9.7% by May.

For context, the 2024–2025 vaccine reduced COVID-related emergency department visits by about 33% in adults and cut hospitalizations by 45–46% among older adults with healthy immune systems. Those aren't blockbuster numbers, but when you're talking about hundreds of thousands of hospitalizations, even modest effectiveness saves a lot of lives and hospital beds. The math only works, though, if people actually get the shot.

What This Means for Fall 2026

The authorization itself is the easy part. Manufacturers can now start shipping doses, pharmacies can start scheduling appointments, and the CDC can update its recommendations. The harder question is whether this fall's campaign can move the needle on uptake.

Pharmacies remain the dominant delivery channel; CDC data shows over 20.8 million doses went through retail pharmacies in the 2025–2026 season compared to just 2.5 million through doctor's offices. That means CVS, Walgreens, and their competitors will once again serve as the front line of America's COVID defense.

The XFG-targeted vaccines represent a genuinely better match to what's circulating right now. The science is solid. The regulatory process worked as designed. The products are authorized and ready to ship. But the biggest variable isn't virology or manufacturing; it's human behavior. And on that front, the track record has been, well, underwhelming.

The vaccines are ready. The question is whether America is.